PHARMATHER HLDGS LTD (PHRRF)
PHRRF moved a median of -0.22% 30 minutes after news, and -1.11% by the close. How PHRRF actually reacts to news — the realized, point-in-time move the market made, measured across 30 labeled events over the last three years with zero look-ahead.
PHRRF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 30 |
| 30-min | -0.22% | 47% | 30 |
| 60-min | -1.05% | 47% | 30 |
| to close | -1.11% | 43% | 30 |
| Middle 50% of PHRRF reactions | -5.67% to +4.57% |
|---|---|
| Median reaction (30-min) | -0.22% |
| Measured reactions | 30 |
Half of all PHARMATHER HLDGS LTD news events land between -5.67% and +4.57% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PHRRF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PHRRF's baseline. Nothing else.
Recent PHRRF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy | Press release | GlobeNewswire | -10.67% | -2.56% | |
| PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments | Press release | GlobeNewswire | -12.86% | -50.89% | |
| PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™) | Press release | GlobeNewswire | +3.12% | -9.23% | |
| PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™) | Press release | GlobeNewswire | +16.41% | +19.26% | |
| PharmaTher Announces FDA Approval of Ketamine (KETARx™) | Press release | GlobeNewswire | -4.33% | -13.33% | |
| PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine | Press release | GlobeNewswire | +4.53% | +3.13% | |
| PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market | Press release | GlobeNewswire | -0.51% | +7.92% | |
| PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications | Press release | GlobeNewswire | -4.78% | -1.65% | |
| PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025 | Press release | GlobeNewswire | -18.29% | -17.14% | |
| PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization | Press release | GlobeNewswire | +0.00% | +0.94% | |
| PharmaTher Receives US FDA Approval Goal Date for Ketamine | Press release | GlobeNewswire | +0.00% | -1.45% | |
| PharmaTher Provides Update on FDA New Drug Application for Ketamine | Press release | GlobeNewswire | -1.62% | +0.00% | |
| PharmaTher CEO Issues Letter to Shareholders | Press release | GlobeNewswire | +0.00% | +6.53% | |
| PharmaTher Announces Grant of Stock Options | Press release | GlobeNewswire | +0.00% | +6.53% | |
| PharmaTher Announces Update on FDA New Drug Application for Ketamine | Press release | GlobeNewswire | +4.48% | +3.66% | |
| PharmaTher Announces Update on FDA New Drug Application for Ketamine | Press release | GlobeNewswire | -0.57% | -2.47% | |
| PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application | Press release | GlobeNewswire | +1.28% | +3.46% | |
| PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application | Press release | GlobeNewswire | -18.60% | -14.29% | |
| PharmaTher Announces Update on FDA New Drug Application for Ketamine | Press release | GlobeNewswire | -9.09% | -2.42% | |
| PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins | Press release | GlobeNewswire | +0.00% | -1.57% | |
| PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine) | Press release | GlobeNewswire | +0.00% | +2.10% | |
| PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine | Press release | GlobeNewswire | +0.00% | -0.78% | |
| PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine | Press release | GlobeNewswire | -3.68% | -9.81% | |
| PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine | Press release | GlobeNewswire | +2.90% | +2.32% | |
| PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine | Press release | GlobeNewswire | +15.16% | +14.44% | |
| PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine | Press release | GlobeNewswire | -2.54% | -8.48% | |
| PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia | Press release | GlobeNewswire | +1.39% | -4.94% | |
| PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine | Press release | GlobeNewswire | +1.44% | -25.83% | |
| PharmaTher Provides Update for Expected FDA Approval of Ketamine | Press release | GlobeNewswire | +1.05% | +3.79% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PHRRF section they belong to.
Where else PHRRF is measured.
PHRRF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is PHARMATHER HLDGS LTD's median reaction calculated?
Every labeled PHRRF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 30 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of PHRRF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PHRRF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.